Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

Prostate

Volumn 41, Issue 2, 1999, Pages 127-133

  Drachenberg, Darrel E ^a,b   Elgamal, Abdel Aziz A ^a   Rowbotham, Ron ^a   Peterson, Mary ^a   Murphy, Gerald P ^a  

^a NORTHWEST HOSPITAL   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Hormone refractory; Interleukin 6; Prostate carcinoma; Prostate specific antigen; Prostate specific membrane antigen

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CHRONIC PROSTATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032880248     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H     Document Type: Article

References (29)

1. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-97.
2. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. Protein Science 1997;6:929-55
3. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of interleukin 6 receptor and interleukin 6 in prostate carcinoma cell lines. Cancer Res 1990;50:7786-88.
4. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign hyperplasia. J Urol 1994;151:1396-99.
5. Twillie DA, Eisenberger MA, Carducci MA, Hseih W, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-49.
6. Hoosein N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis C. Clinical significance of elevation in neuroendocrine factors and Interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246-51.
7. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating Interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-87.
8. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
9. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;48:8-31.
10. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointer J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH. Evaluation and comparison of two new prostate carcinoma markers: free-prostate specific antigen and prostate specific membrane antigen. Cancer 1996;78:809-818.
11. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate-specific membrane antigen. Cancer 1998;83:2259-69.
12. Murphy GP, Ragde H, Kenny G, Barren RJ, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T. Comparison of prostate specific membrane antigen and prostate specific antigen levels in prostate cancer patients. Anticancer Res 1995;15: 1473-80.
13. Dawson NA. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 1998;16:33398-405.
14. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-45.
15. Liu KJ, Charta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis. J Immunol 1997;159:472-80.
16. Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. J Urol 1994;152:247-50.
17. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Bio 1993;120:1281-88.
18. Hobish A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 activates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640-45.
19. Gleave ME, Drachenberg DE, Coupland DB, Sullivan LD, Goldenberg SL. Ability of serum PSA levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996;47:708-12.
20. Narayan P, Fournier G, Gajendran V. Utility of preoperative serum prostate-specific antigen concentration and biopsy score in predicting risk of pelvic lymph node metastasis in prostate cancer. Urology 1994;44:519-24.
21. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Inv 1996;14:513-17.
22. ® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998;38:261-69.
23. Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 1996;156:1042-49.
24. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong ENP, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-1547.
25. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and alpha-1-antichymotrypsin is the major form of PSA in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:221-28.
26. rd Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), Montreal, Canada, September 10-13, 1995.
27. Wojno KJ, Vashi AR, Schellhammer PF, Wright GL, Montie JE. Percent free prostate specific antigen values with recurrent prostate cancer after radical prostatectomy. Urology 1998;52: 474-78.
28. Wright GL Jr, Grob M, Haley C, Grossman K, Newhall K, Petrylak D. Upregulation of prostate-specific membrane antigen after androgen deprivation therapy. Urology 1996;48:326-34.
29. Kawakami M, Nakayama J. Enhanced expression of prostatespecific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-24.